Objective: Castleman disease (CD) comprises a heterogeneous group of disease with various clinical presentations and prognosis. By definition; CD is a lymphoproliferative disorder of the mediastinal lymph nodes and extranodal tissues with follicular and interfollicular abnormalities. Pleural localization is an unusual presentation of CD. Method: A 27-year-old man applied to the hospital because of cough. Chest x-ray and CT images showed an irregular, 35×56×67 mm sized intrapleural-extrapulmoner mass in the paramediastinal region. Surgical specimen was consisting of a 7×5×3.5 cm sized, irregular-round shaped, gray colored calcified mass. Microscopically, a lymphoid proliferation with distorted follicles and increased dendritic cells (with CD21) was detected. Lymphocyte depleted germinal centers resembling "onion skin" appearance with penetrated sclerosing hyalinized blood vessels were also seen. Interfollicular region was composed of proliferating blood vessels lined by plump endothelial cells and few lymphoplasmositer infiltration. There was heterogeneous positivity with CD3 and CD20. Expanded mantle zones showed diffuse bcl2 positivity. Ki67 proliferation index was low. The mass was diagnosed as "Castleman Disease, hyaline vascular type". Typical appearance of the follicular and interfollicular abnormalities allowed definitive differentiation from mesothelioma and solitary fibrous tumor of the pleura. Conclusion: Pleural CD is a rare lesion but should be considered especially on young patients in the differential diagnosis of pleural masses. Objective: To evaluate FOXp3 expression in bronchus-associated lymphoid tissue (BALT) and correlate with the inflammatory process and collagen content in the lung tissue in an experimental model of scleroderma (SSc) after type V collagen (COL V)-induced nasal tolerance. Method: Female New Zealand rabbits (N=12) were immunized with 1 mg/ml of COL V in Freund's adjuvant (IM). After 150 days, six immunized animals were nasally tolerated with COL V (25 νg/day), during 60 days (IM-TOL). Animals (N = 6) only tolerated served as control (CT). FOXP3 expression in BALT and inflammatory cells in pulmonary interstitium were evaluated by point counting method. Types I, III and V collagen gene expression were evaluated by Real-time PCR. Results: IM-TOL when compared to IM presented decreased lymphocytes, macrophages and monocytes and types I (p=0,002) and V (p=0,009) collagen mRNA expression in pulmonary tissue. T lymphocytes FOXp3 were expressed in 100 % of IM-TOL and 33,3 % of CT (p= 0,03). Additionally, BALT was higher expressed in IM-TOL in relation to CT. Conclusion: COL V-induced nasal tolerance in SSc model induces FOXp3 regulatory T cells in BALT which can trigger an immune regulatory mechanism resulting in decreased inflammation and collagen expression. It suggests that COL V tolerance could be a promising therapeutic for human scleroderma treatment.